This is a modal window.
Beginning of dialog window. Escape will cancel and close the window.
End of dialog window.
targeting acute, life threatening and chronic inflammatory diseases with new and selective inhibitors of the C5a/C5aR signaling pathway of the immune system's complement cascade.
To learn more about our ongoing phase 3 trial for treating ulcerative pyoderma gangrenosum, please visit clinicaltrials.gov
InflaRx is developing highly specific therapeutics targeting the C5a/C5aR signaling axis of the complement system. InflaRx has made breakthrough discoveries in the area of selective anti-C5a antibody generation and C5a receptor (C5aR) inhibitors.
InflaRx focuses on diseases with high unmet medical need. Vilobelimab, the company's first-in-class anti-human C5a monoclonal antibody is currently being developed in several chronic inflammatory diseases, as well as oncology and for the treatment of critically ill COVID-19 patients.
Gohibic (vilobelimab) - FDA has issued an emergency use authorization (EUA) to treat certain critically ill COVID-19 patients.
The latest information on InflaRx share price with interactive charts, comparative analysis, historic figures and latest trade price is available here.
Jena, Germany, October 31, 2024 – InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneerin...
Jena, Germany, September 25, 2024 – InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneer...
Jena, Germany, September 3, 2024 – InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneeri...
Jena, Germany, August 27, 2024 – InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering...
Jena, Germany, January 23, 2025 – InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneerin...
Jena, Germany, January 15, 2025– InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering...
Jena, Germany, January 7, 2025 – InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering...
Jena, Germany, December 20, 2024 – InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneeri...
Jena, Germany, November 15, 2024 – InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneeri...
Jena, Germany, November 8, 2024 – InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneerin...
Jena, Germany, October 31, 2024 – InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneerin...
Jena, Germany, September 25, 2024 – InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneer...
Jena, Germany, September 3, 2024 – InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneeri...
Jena, Germany, August 27, 2024 – InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering...
Jena, Germany, January 23, 2025 – InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneerin...
Jena, Germany, January 15, 2025– InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering...
Jena, Germany, January 7, 2025 – InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering...
Jena, Germany, December 20, 2024 – InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneeri...